Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1)

NCT07723248 is registered in ClinicalTrials.gov with ORIC Pharmaceuticals as lead sponsor.

NCT NCT07723248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07723248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination With Darolutamide Compared With ARPI or Docetaxel in Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Abiraterone Acetate (Himalayas-1)
Lead sponsor
ORIC Pharmaceuticals
Phase
Phase 3
Overall status
Recruiting
Start date
August 3, 2026
Completion date
September 30, 2030
Enrollment
600 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer